By Dr Alex Thompson, Lecturer in sensing in cancer
World Cancer Day provides an opportunity both to celebrate the huge progress that has been made in the fight against cancer and to remember the challenges that lie ahead. While cancer survival has doubled in the UK over the last 40 years, the disease still causes more than one out of every four UK deaths.
By Mr Daniel Leff, Reader in Breast Surgery, Department of Surgery & Cancer, Faculty of Medicine
As we move towards the end of Breast Cancer Awareness month
, it is important to celebrate the many success of breast cancer research and treatment – whilst breast cancer may be common, more women than ever before are surviving thanks to earlier diagnosis and an improved understanding of the biology of breast cancer leading to more personalised medicine. That said, we still face major challenges. The one that is on the forefront of my mind is the “margins problem” once called the ‘hidden epidemic of breast cancer’.
By Professor Simon Taylor-Robinson, Consultant Hepatologist and Professor of Translational Medicine at Imperial College London
Cholangiocarcinoma is a rare primary malignancy arising from cholangiocytes, the endothelial lining of the biliary ducts, with an incidence 2500 cases of per annum in the UK. The only option for cure is surgical resection, but cholangiocarcinoma usually presents late when it grows sufficiently to block the drainage of bile from the liver, presenting with jaundice. By this point it is often irresectable, and palliative management includes holding open the ducts with stents to prevent blockage, and chemotherapy. One-year survival is only 5%.
The incidence of this insidious disease is increasing, and earlier diagnosis and better treatment are urgently required.
By Caitriona Tyndall, MSc. BSc, Cancer Research UK Imperial Centre, Department of Surgery and Cancer, Imperial College London.
The 4th of February is World Cancer Day. This is a day to remember and celebrate. Sadly cancer affects us all whether it’s personally or through our friends and family or work colleagues. In fact it’s estimated that 1 in 2 of us will be affected by cancer at some point in our lifetime. But in the face of this depressing statistic there is cause to celebrate. We can celebrate the people we know who have beaten cancer, celebrate the lives of those we have lost and celebrate the ground-breaking research being done by thousands of people across the UK and the world to help beat cancer sooner.
By guest blogger, Dr Yu Zhi Zhang (Dennis), Clinical Research Fellow and Specialist Registrar in Histopathology at the National Heart and Lung Institute (NHLI), Imperial College London; on behalf of the National Centre for Mesothelioma Research (NCMR), National Heart and Lung Institute (NHLI), Imperial College London
The 9th edition of the renowned Osler’s Textbook on the Principles and Practice of Medicine, published in 1921, dedicated only two (out of 1,139) pages to lung cancer, at which point the condition was described as “New Growths in the Lungs”. Almost a hundred years on, the patterns of epidemiology have shifted drastically, and lung cancer now is recognised as a major health problem globally with more than 1.8 million new cases diagnosed every year.
By guest blogger Chanice Henry, Editor, Pharma IQ
In the fight against one of the world’s most widespread diseases, new research has found that pharmacists are key in the optimisation of medical treatment for breast cancer patients.
Breast cancer is the most common cancer that occurs in women. In 2012 there were 1.7 million new diagnoses – which equated to 12% of all new cancer cases. Less than one per cent of breast cancer develops in males.
Despite its prevalence, death rates from this form of cancer have been consistently declining over the past 25 years due to better awareness and advancing treatment options.
By Dr Jon Krell, Principal Investigator within the Ovarian Cancer Action Research Centre (OCARC), a collaborative, multi-disciplinary team of clinicians and scientists, focused on translational research to improve outcomes for women with ovarian cancer.
March is Ovarian Cancer Awareness Month, and an opportunity to highlight a key part of our Centre’s research programme aimed at improving early diagnosis and identifying risk factors.
By Gianpaolo Fusari and Madeleine Maxwell at the Helix Centre for Design in Healthcare, a multi-disciplinary team of designers, technologists, researchers and clinicians based at St. Mary’s Hospital, using human-centred design methods to tackle problems in healthcare.
Over 41,000 people are diagnosed with bowel cancer every year in the UK, and at 16,000 deaths per year, it is the second most common cause of cancer death in the UK behind lung cancer.
By Student Challenges Competition 2015/16 Audience Choice Award winners, Antonios Chronopoulos and Tyler Lieberthal
Pancreatic cancer has the lowest survival rate of all major cancers and is widely regarded as a death sentence. The 5-year survival rate is still in the single digits at 3% and this figure has not changed over the past four decades largely due to lack of specific therapies and inability of early detection. Symptoms rarely develop with early disease, which translates to more than 85% of patients receiving their diagnosis at an advanced stage when the tumour is metastatic and no longer treatable. Modern imaging techniques, such as CT and MRI are expensive and unable to detect early-stage lesions.
By Imperial medical students Thomas Hughes and Thomas O’Connor
Today, 17th February 2016, marks the first ever World Cholangiocarcinoma Day.
Cholangiocarcinoma (CCA) is a primary liver cancer, usually formed from glandular structures in the epithelial tissue (adenocarcinomatous). It occurs in the bile ducts and is classed as being either intra-hepatic (IHCC) or extra-hepatic (EHCC) depending on whether the tumour forms inside or outside of the liver.
CCA is the second most common form of primary hepatic malignancies in the world, with survival beyond a year of diagnosis being <5%. It represents 30% of primary hepatic malignancies with a mean survival rate of 3-6 months after diagnosis, due mostly to the late presentation of symptoms which massively reduces treatment success rates.